Chronic myelogenous leukemia is a myeloproliferative disorder characterized by the t(9:22) (q34:q11) reciprocal translocation, resulting in the expression of the chimeric Bcr–Abl oncoprotein with constitutive tyrosine kinase activity. Deregulated Bcr–Abl induces the hyperactivation of various signalling pathways involved in cell growth, apoptosis and cell adhesion.
Raimondo, S., Corrado, C., Taverna, S., Flugy, A., De Leo, G., Alessandro, R. (2012). In vitro and in vivo effect of CarboxyAmido-Triazole Orotate (CTO) on Imatinib resistant Chronic Myelogenous Leukemia cells. In RIKEN RCAI International Summer Program. Yokohama, Japan, June 22-27.
In vitro and in vivo effect of CarboxyAmido-Triazole Orotate (CTO) on Imatinib resistant Chronic Myelogenous Leukemia cells
RAIMONDO, Stefania;CORRADO, Chiara;TAVERNA, Simona;DE LEO, Giacomo;ALESSANDRO, Riccardo
2012-01-01
Abstract
Chronic myelogenous leukemia is a myeloproliferative disorder characterized by the t(9:22) (q34:q11) reciprocal translocation, resulting in the expression of the chimeric Bcr–Abl oncoprotein with constitutive tyrosine kinase activity. Deregulated Bcr–Abl induces the hyperactivation of various signalling pathways involved in cell growth, apoptosis and cell adhesion.
| File | Dimensione | Formato | |
|---|---|---|---|
|
riken.pdf
Solo gestori archvio
Dimensione
371.35 kB
Formato
Adobe PDF
|
371.35 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
